Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Oculis Holding AGNASDAQ: OCS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of CHF 28.95M (cash outflow) fell 12.8% year over year, behind the -8.3% change in trailing-twelve-month net income. Sequentially, it rose 24.1% from the prior quarter. Over 3 fiscal years it compounded at +34.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -CHF 74.81M (-20.8%) for the fiscal year ending Dec 2026, a slowdown from the +10.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CHF 28.95M+24.1% QoQ
- Last fiscal yearDec 2025
- -CHF 94.51M+10.0% YoY
- LTMMar 2026
- -CHF 94.54M-8.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.8% | -6.1% | +6.7 pp |
| 1 year | +10.0% | -20.8% | -30.8 pp |
| 3-year CAGR | +34.7% | +0.7% | -34.0 pp |
| 5-year CAGR | -39.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CHF · from the cash flow
- Latest · FY2025
- (94.51M) CHF
- Year-over-year change
- -10.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (94.51M) | -10.0% |
| FY2024 | 2024-12-31 | (85.94M) | +3.1% |
| FY2023 | 2023-12-31 | (88.7M) | -129.5% |
| FY2022 | 2022-12-31 | (38.64M) | -108.6% |
| FY2021 | 2021-12-31 | (18.52M) | — |
Net Income vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.3% is the 3rd highest of 6, against a peer median of -31.0%.
- Net income amounts to 18758.0% of revenue for OCS, versus a peer median of 2062.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $290.5M USD | +50.7% | +55.3% | 558.2% | |
| LTM Mar 2026 | $271.6M USD | +85.0% | +31.4% | 3566.6% | |
| LTM Mar 2026 | CHF 94.54M CHF | -8.3% | +34.7% | 18758.0% | |
| LTM Mar 2026 | $60.96M USD | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $14.96M USD | -31.0% | -28.5% | 5.6% | |
| FY2025 | $7.97M USD | -52.6% | +8.6% | — | |
| Peer median (excluding OCS) | — | -31.0% | +8.6% | 2062.4% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.51M) |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 328K | 804K | 3.61M | 9.78M | 16.04M |
| Change in Working Capital | (791K) | 6M | (12.99M) | 14.16M | (70.67K) |
| Accounts Receivables | 233K | (152K) | 36K | 247K | 1.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30K | 3.04M | 3.73M | (1.71M) | (1.86M) |
| Other Working Capital | (1.05M) | 3.11M | (16.76M) | 15.62M | (106.97K) |
| Other Non-Cash Items | 4.93M | 6.47M | 43.95M | 14.09M | 15.77M |
| Operating Cash Flow | (13.83M) | (25.07M) | (53.85M) | (47.5M) | (62.22M) |
| Capital Expenditures | (28K) | (3.55M) | (48K) | (230K) | (287.47K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (54.16M) | (17.33M) | (58.05M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.48M) | 0 | 0 | 0 |
| Investing Cash Flow | (28K) | (3.55M) | (54.21M) | (17.56M) | (59.38M) |
| Debt Repayment | (98K) | (159K) | (158K) | (274K) | (373K) |
| Common Stock Issued | 0 | 0 | 135.62M | 53.54M | 178.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (804K) | (157K) | (5.79M) | 763K | 16.77K |
| Financing Cash Flow | 55.19M | 1.71M | 129.67M | 54.03M | 178.6M |
| Effect of Forex Changes | (16K) | 418K | (3.08M) | 407K | 174.39K |
| Net Change in Cash | 41.33M | (26.49M) | 18.54M | (10.62M) | 57.17M |
| Free Cash Flow | (13.85M) | (28.62M) | (53.89M) | (47.73M) | (62.51M) |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.